BIOMAT Database Logo BIOMAT Database Logo

[Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent]. 1991

T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Tokyo, Japan.

In screening of new antifungal agents, bis(naphthalenemethyl)amines were found to have more potent antifungal activity than clotrimazole. Studies on their structure-activity relationships indicated that benzylamines had potent antifungal activity. Among them, butenafine hydrochloride (N-p-tert-butylbenzyl-N-methyl-1-naphthalenemethylamine hydrochloride, KP-363) has proved to show the strongest activity. It exhibits a wide spectrum activity in vitro against particularly dermatophytes (87 strains; minimal inhibitory concentration (MIC) range, 0.0015 to 0.05 microgram/ml), and also against Aspergillus (15 strains; MIC range, 0.025 to 0.78 microgram/ml), Cryptococcus neoformans (4 strains; MICs 0.78 and 1.56 micrograms/ml) and yeasts of genus Candida (67 strains; MIC range, 3.13 to greater than 100 micrograms/ml).

UI MeSH Term Description Entries
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D001596 Benzylamines Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group. Phenylmethylamine,alpha-Aminotoluene,alpha Aminotoluene
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs.
November 1990, Antimicrobial agents and chemotherapy,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs.
November 1990, Antimicrobial agents and chemotherapy,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
The antifungal agent butenafine manifests anti-inflammatory activity in vivo.
August 1999, Journal of the American Academy of Dermatology,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Synthesis and Structure-Activity Relationships of Novel Benzylamine-Type Antifungals as Butenafine-Related Antimycotics.
May 2017, Archiv der Pharmazie,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
July 1993, Journal of medicinal chemistry,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent.
August 1997, Journal of the American Academy of Dermatology,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities.
November 2018, Journal of advanced research,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
In vitro antifungal activity of ZJ-522, a new triazole restructured from fluconazole and butenafine, against clinically important fungi in comparison with fluconazole and butenafine.
August 2005, Biological & pharmaceutical bulletin,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent.
August 1979, Journal of medicinal chemistry,
T Maeda, and M Takase, and A Ishibashi, and T Yamamoto, and K Sasaki, and T Arika, and M Yokoo, and K Amemiya
In vitro activity of ME1401, a new antifungal agent.
November 1986, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!